Logomix’s core competence is Geno-Writing™ platform: a collective knowledge and technologies that enable Mb-scale design and re-construction of human and the other mammalian genomes to create newly functionalized cells. Currently, Logomix provides human model cells of diseases that are caused (or are hypothesized to be caused) by larger chromosomal structural modification than simple indels, such as triplet repeat diseases and pathogenic CNVs.